

Supplementary file 1 Summary table of the incremental cost-effectiveness ratio (in THB/QALY gained) of each technology compared and the coverage decisions.

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
1	Tamteeranon et al., 2007	High risk for acute coronary syndrome in male with >30% risk	Simvastatin (generic)	No statin	87,781	Yes
			Combinations of statins usage		248,953	No
			Atorvastatin		672,899	No
			Pravastatin		640,198	No
		High risk for acute coronary syndrome in female with 15-20% risk	Simvastatin (generic)	No statin	136,928	Yes
			Combinations of statins usage		372,942	No
			Atorvastatin		918,633	No
			Pravastatin		895,607	No
2	Reungrong et al., 2007	Chemotherapy-induced anemia with Hb <8 g/dL	Recombinant human erythropoietin (rHuEPO)	Blood transfusion	344,582	Yes
		Chemotherapy-induced anemia with Hb 8-9 g/dL	Recombinant human erythropoietin (rHuEPO)		242,389	
		Chemotherapy-induced anemia with Hb 9-10 g/dL	Recombinant human erythropoietin (rHuEPO)		Existing treatment dominates	
3	Limwattananon et al., 2011	Diffused large B-cell lymphoma	Rituximab and CHOP regimen (Cyclophosphamide + Doxorubicin + Vincristine + Prednisolone)	CHOP regimen (cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone)	606,061	Yes*
		Relapsed follicular lymphoma	CVP (Cyclophosphamide, Vincristine and Prednisolone)		583,473	No
4	Turongkaravee et al., 2011	Mild-to-moderate Alzheimer's disease	Galantamine	Palliative care	157,247	No
			Donepezil		242,766	Yes
			Rivastigmine		176,740	No

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
5	Deepana et al., 2011	Metastatic clear cell renal cell carcinoma (ccRCC)	IFN-alpha (1st line)	Palliative care	593,000	No
			Bevacizumab with IFN-alpha (1st line)		4,842,000	
			Sunitinib (1st line)		2,389,000	
			IFN-alpha (1st line) + Sorafenib (2nd line)		1,665,000	
			Sunitinib (1st line)+ Everolimus (2nd line)		2,546,000	
			Bevacizumab with IFN-alpha (1st line) + everolimus (2nd line)		4,521,000	
6	Mohara et al., 2012	Nonresectable or metastatic Gastrointestinal stromal tumor (GISTs)	High-dose Imatinib	Current practice (Standard-dose Imatinib + palliative care)	4,451,545	Yes
			High-dose Imatinib followed by Sunitinib		3,921,127	
			Sunitinib		2,479,847	
7	Tanmukayakul et al., 2012	Gaucher disease type 1, treated at age 2	Imiglucerase	Palliative care	1,184,128	Yes*
		Gaucher disease type 1, treated at age 20			6,370,970	No
8	Chaiyakunapruk et al., 2012	Dermatomyositis	Intravenous immunoglobulin (IVIG) + Steroids	Standard care (Intravenous steroid + immunosuppressant)	Dominant	Yes
9	Chaiyakunapruk et al., 2012	Chronic inflammatory demyelinating polyneuropathy (CIDP)	Intravenous immunoglobulin (IVIG) + Steroids and immunosuppressant if inadequate response to IVIG	intravenous steroid + immunosuppressant if no response from steroids (standard care)	155,121	Yes
10	Chaiyakunapruk et al., 2012	Idiopathic thrombocytopenic purpura (ITP) - Adults	Intravenous immunoglobulin (IVIG)	Intravenous steroid	2,295,515	Yes

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
		Idiopathic thrombocytopenic purpura (ITP) - Children	Intravenous immunoglobulin (IVIg)	Intravenous steroid	87,562	Yes
11	Kulpeng et al., 2012	Chronic myeloid leukemia (CML) with resistance to standard dose Imatinib	Dasatinib	High-dose imatinib	Dominant	Yes*
			Nilotinib	High-dose imatinib	86,698	Yes*
12	Thongsri et al., 2012	Pulmonary arterial hypertension relating to Connective tissue disorder-CTD level II	Sildenafil (first line treatment)	Standard care (Digoxin, Diuretic, Anticoagulant and Oxygen therapy)	168,509	Yes*
			Beraprost (first line treatment)	Standard care (Digoxin, Diuretic, Anticoagulant and Oxygen therapy)	111,858	No
			Sildenafil (first line treatment)	Beraprost	226,687	Yes
		Pulmonary arterial hypertension relating to Connective tissue disorder-CTD level III	Sildenafil (first line treatment)	Standard care (Digoxin, Diuretic, Anticoagulant and Oxygen therapy)	168,380	Yes
			Beraprost (first line treatment)	Standard care (Digoxin, Diuretic, Anticoagulant and Oxygen therapy)	147,227	No
			Sildenafil (first line treatment)	Beraprost	175,615	Yes
		Pulmonary arterial hypertension relating to Connective tissue disorder-CTD level II after failing first line treatment	Beraprost + Beraprost and Sildenafil (second line combination therapy)	Beraprost switch to standard care	94,240	No
			Sildenafil + Sildenafil and Iloprost (second line combination therapy)	Sildenafil switch to standard care	757,756	
			Sildenafil + Sildenafil and Bosentan (second line combination therapy)		453,947	

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?	
			Sildenafil to Iloprost (second line switch therapy)		728,977		
			Sildenafil to Bosentan (second line switch therapy)		426,625		
			Beraprost + Beraprost and Sildenafil (second line combination therapy)		Beraprost switch to standard care		289,930
			Sildenafil + Sildenafil and Iloprost (second line combination therapy)		Sildenafil switch to standard care		1,613,759
			Sildenafil + Sildenafil and Bosentan (second line combination therapy)				1,100,938
			Sildenafil to Iloprost (second line switch therapy)		1,548,817		
			Sildenafil to Bosentan (second line switch therapy)		1,023,056		
			Pulmonary arterial hypertension relating to congenital heart disease (PAH-CHD) level II		Beraprost (first line treatment)		Standard care
		Sildenafil (first line treatment)		243,152	Yes		
		Pulmonary arterial hypertension relating to congenital heart disease (PAH-CHD) level III	Beraprost (first line treatment)		189,596	No	
Sildenafil (first line treatment)	219,605		Yes				
13			Erlotinib 150 mg	Docetaxel 75 mg/m ²	2,092,500	No	

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
	Limwattananon et al., 2012	Locally advanced or metastatic stage IIIB-IV non-small cell lung cancer with EGFR positive that failed first line treatment	Gefitinib 250 mg	Docetaxel 75 mg/m ³	1,467,672	
14	Tangwongsiri et al., 2012	Moderate to severe chronic plaque psoriasis	Eternacept	Ustekinumab	-13,510,263	No
		Moderate to severe chronic plaque psoriasis	Infliximab		6,719,775	
15	Kumdee et al., 2012	Unresectable malignant pleural mesothelioma	Pemetrexed 500 and 100 mg with Cisplatin 50 mg	Gemcitabine 200 and 1000 mg + Cisplatin 50 mg	1,726,084	No
			Pemetrexed 500 mg with Cisplatin 50 mg		1,835,695	
			Pemetrexed 100 mg/m ² with Cisplatin 50 mg		2,123,351	
			Pemetrexed 500 and 100 mg with Carboplatin 450 mg		707,592	
			Pemetrexed 500 mg/m ² + Carboplatin 450 mg		733,959	
			Pemetrexed 100 mg/m ² + Carboplatin 450 mg		803,156	
16	Maneeon et al., 2012	Treatment naïve Intermediate stage or unresectable Hepatocellular carcinoma (HCC)	Transarterial chemoembolization (TACE) with Iodized oil fluid injection (Lipiodol® Ultra Fluid)	Best supportive care	399,076	No
			Drug-eluting beads (DEB-TACE)	Best supportive care	369,811	
17			Alendronate	Calcium and vitamin D	112,725	No

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?		
	Kingkaew et al., 2013	Primary prevention for osteoporotic fractures	Risedronate		3,534,000			
			Raloxifene		881,562			
			Tibolone		537,187			
		Secondary prevention for osteoporotic fractures	Alendronate		335,608			
			Risedronate		749,497			
			Ibandronate		805,716			
			Zoledronic acid		343,535			
			Tibolone		701,844			
			Strontium renelate		4,232,768			
			Teriparatide		11,755,274			
			18		Thongsri et al., 2014		Prostate cancer with Intermediate risk	Goserelin and Flutamide
Leuprorelin and Flutamid	91,136							
Triptorelin and Flutamide	93,043							
Prostate cancer with high and very high risk	Goserelin and RT	Surgery		109,983		No		
	Goserelin and Flutamide and RT			169,731		No		
	Leuprorelin and Flutamide and RT			137,613		Yes		
	Triptorelin and Flutamide and RT			119,429		Yes		
Metastatic prostate cancer	Goserelin					-9,337,900	No	
	Leuprorelin					-34,881,375	Yes	
	Triptorelin					69,778,000	Yes	
	Buserelin					-4,371,226	No	
19	Tantai et al., 2014		HBeAg-positive chronic hepatitis B	Generic lamivudine (tenofovir)	Palliative care	-14314	Yes	
				Generic lamivudine (tenofovir)		-7555	Yes	
				Tenofovir monotherapy		-5159	Yes	
		Original lamivudine (tenofovir)		81,000		Yes		

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
			Pegylated interferon (original lamivudine) tenofovir		84,000	No
			Original lamivudine (tenofovir)		88,000	Yes
			Generic lamivudine (adefovir)		90,000	Yes
			Pegylated interferon (tenofovir)		105,000	No
			Telbivudine (tenofovir)		112,000	Yes
			Generic lamivudine (adefovir)		121,000	No
			Telbivudine (tenofovir)		121,000	Yes
			Pegylated interferon (original lamivudine) tenofovir		158,000	No
			Adefovir (generic lamivudine)		167,000	
			Pegylated interferon (lamivudine) adefovir		167,000	
			Telbivudine (adefovir)		178,000	
			Pegylated interferon (telbivudine) tenofovir		181,000	
			Original lamivudine (adefovir)		186,000	
			Entecavir (tenofovir)		197,000	
			Entecavir (adefovir)		200,000	
			Adefovir (original lamivudine)		202,000	
			Original lamivudine (adefovir)		216,000	
			Pegylated interferon (adefovir) generic lamivudine		222,000	
			Telbivudine (adefovir)		224,000	
			Pegylated interferon (telbivudine) adefovir		233,000	

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
			Pegylated interferon (original lamivudine) adefovir		241,000	
			Pegylated interferon (entecavir) tenofovir		246,000	
			Pegylated interferon (entecavir) adefovir		249,000	
			Pegylated interferon (adefovir) original lamivudine		255,000	
20	Lerdkiatkorn et al., 2014	Advance colorectal cancer	5-fluorouracil/leucovorin (5-FU/LV) + Fluorouracil/leucovorin/oxaliplatin (FOLFOX)	5-fluorouracil/leucovorin (5-FU/LV) + Capecitabine	5,205,000	Yes* (oxaliplatin)
			5-fluorouracil/leucovorin (5-FU/LV) + Capecitabine/oxaliplatin (XELOX)		-62500000	Yes
			5-fluorouracil/leucovorin (5-FU/LV) + Irinotecan plus 5-FU/LV (FOLFIRI)		14,567,000	No
			Capecitabine + Fluorouracil/leucovorin/oxaliplatin (FOLFOX)		855,000	Yes
			Capecitabine + Capecitabine/oxaliplatin (XELOX)		1,055,000	Yes
			Capecitabine + Irinotecan plus 5-FU/LV (FOLFIRI)			No
			Fluorouracil/leucovorin/oxaliplatin (FOLFOX) + Irinotecan plus 5-FU/LV (FOLFIRI)		474,000	Yes
			Capecitabine/oxaliplatin (XELOX) + Irinotecan plus 5-FU/LV (FOLFIRI)		707,000	Yes

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
21	Yamwong et al., 2014	Acute coronary syndrome	Ticagrelor + Aspirin (ASA)	Generic Clopidogrel + ASA	292,504	Yes
				Branded Clopidogrel + ASA	60,055	
22	RattanaVIPapong et al., 2014	HIV patient treating with peginterferon alfa-2a and ribavirin (Peg2a+RBV)	Screening for Hepatitis C	No screening	-84,943	Yes
		HIV patient treating with peginterferon alfa-2b and ribavirin (Peg2b+RBV)			-101,043	Yes
23	Lerdkiatikorn et al., 2015	Resectable metastatic colorectal cancer (stage III)	5FULV (5-fluorouracil / leucovorin) + FOLFIRI	5-fluorouracil / leucovorin + palliative care	610,178	No
			FOLFOX (5-Fluorouracil+Leucovorin+Oxaliplatin) + palliative care		376,310	Yes
			FOLFOX (5-Fluorouracil+Leucovorin+Oxaliplatin) + FOLFIRI (5-Fluorouracil+Leucovorin+Irinotecan)		461,549	Yes
			XELOX (Oxaliplatin+Capecitabine) + palliative care		404,988	No
			XELOX (Oxaliplatin+Capecitabine) + FOLFIRI (5-Fluorouracil+Leucovorin+Irinotecan)		464,556	
			FOLFIRI + FOLFOX (5-Fluorouracil+Leucovorin+Oxaliplatin)		1,116,282	Yes
			Capecitabine + FOLFIRI (5-Fluorouracil+Leucovorin+Irinotecan)		843,047	No

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
24	DAIICHI SANKYO (THAILAND) LTD. 2015	Patients with acute coronary syndrome (overall) who received percutaneous coronary	Prasugrel	Clopidogrel	114,000	No
					98,000	
					52,000	
					123,000	
25	Rattanavipapong et al., 2015	Chronic hepatitis C virus infection (genotype 3)	Genotyping, Sofosbuvir and PR	Genotyping and peg-interferon and ribavirin (PR) 24 weeks	-166667	Yes*
			Genotyping, Sofosbuvir and Sofosbuvir and Ledipasvir 12 weeks		-166667	Yes
		Chronic hepatitis C virus infection (all genotypes)	Sofosbuvir and peg-interferon alpha and ribavirin (PR) 12 weeks		-165693	Yes*
			Sofosbuvir and Daclatasvir 12 weeks		16581	No
26	2015	HIV patient who failed first-line regimen	Darunavir/ritonavir (DRV/r) + Etravirine (ETR) + Tenofovir (TDF) + Lamivudine (3TC)	Current practice (DRV/r + TDF +3TC)	1196511	No
			Darunavir/ritonavir (DRV/r) + Raltegravir (RAL) + Tenofovir (TDF) + Lamivudine (3TC)		958,932	Yes
			Darunavir/ritonavir (DRV/r) + Raltegravir (RAL) + Etravirine (ETR)		1,286,899	No
			Darunavir/ritonavir (DRV/r) + Raltegravir (RAL) + Maraviroc (MVC)		1343777.412	
27	Yupetch et al., 2016	HIV patient who failed first-line regimen and alternative regimen	Darunavir/ritonavir (DRV/r) + Etravirine (ETR) + TDF +3TC	Current practice (DRV/r + TDF +3TC)	444,128	No
			Darunavir/ritonavir (DRV/r) + Raltegravir (RAL) + TDF +3TC		328,696	
			Darunavir/ritonavir (DRV/r) + Raltegravir (RAL) + Etravirine (ETR)		419,768	

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?	
			Darunavir/ritonavir (DRV/r) + Raltegravir (RAL) + Maraviroc (MVC)		444,310		
			Darunavir/ritonavir (DRV/r) + Dolutegravir (DTG) + Maraviroc (MVC)		399,831		
			Darunavir/ritonavir (DRV/r) + Dolutegravir (DTG) + Etravirine (ETR)		376,939		Yes
			Darunavir/ritonavir (DRV/r) + Dolutegravir (DTG) + Tenofovir (TDF) + Lamivudine (3TC)		187,615		No
28	Thiboonboon et al 2017	Glioblastoma with methylated MGMT (MGMT GBM)	Temozolomide + concomitant therapy + adjuvant therapy	Adjuvant therapy	572,486	No	
		Glioblastoma (all)	Temozolomide + concomitant therapy + adjuvant therapy		808,822		
		Anaplastic Astrocytoma	Adjuvant therapy	Standard care	805,124		
29	Pantumongkol et al., 2017	Multiple Myeloma (MM)	Bortezomib-based regimens	High-dose dexamethasone	9,908,461	No	
			Thalidomide-based regimens		10,706,411		
			Lenalidomide-based regimens		12,009,328		
30	Limwattananon et al., 2018	Patients with stage IIIB/IV, advanced non-small cell lung cancer (NSCLC), who previously had neither chemotherapy nor TKIs	EGFR test + Gefitinib, if the test shown M+ and otherwise platinum doublets if the test shown M-	Platinum doublets for mixed M +/M- patients without the EGFR test	2050593	No	
			EGFR test + Erlotinib, if the test shown M+ and otherwise platinum doublets if the test shown M-		1,511,559		Yes

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
			EGFR test + Afatinib, if the test shown M+ and otherwise platinum doublets if the test shown M-)		6,428,430	No
31	Kittiratchakul et al., 2018	Systemic juvenile idiopathic arthritis who failed standard care	Tocilizumab + current practice	Current practice	1,116,928	Under consideration
32	Kingkaew et al., 2019	Relapsing-remitting multiple sclerosis	Interferon beta-1a + Interferon beta-1a + usual care	Usual care	18,948,000	Under consideration
			Interferon beta-1a + Fingolimod + usual care		23,753,000	
			Interferon beta-1a + Natalizumab + usual care		19,666,000	
			Interferon beta-1a + Fingolimod + Alemtuzumab		16,364,000	
			Interferon beta-1a + Natalizumab + Alemtuzumab		15,856,000	
			Teriflunomide + Teriflunomide + usual care		83,300,000	
			Teriflunomide + Fingolimod + usual care		88,187,000	
			Teriflunomide + Natalizumab + usual care		42,723,000	
			Teriflunomide + Fingolimod + Alemtuzumab		31,070,000	
			Teriflunomide + Natalizumab + Alemtuzumab		27,163,000	
33	Kongsakon et al., 2019	Early-stage breast cancer	Adjuvant therapy with trastuzumab combined with paclitaxel	Traditional chemotherapy with paclitaxel alone	118572	Yes

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
34	Leelahavarong et al., 2020	Rheumatoid arthritis with high disease activity	Etanercept	Cyclosporine or Azathioprine with Methotrexate	2,758,899	Under consideration
			Infliximab		4,894,589	
			Golimumab		5,433,408	
			Tocilizumab		2,443,876	
			Rituximab		2,585,849	
			Tofacitinib		2,616,530	
			Baricitinib		2,327,339	
			Biosimilar of infliximab (Remsima)		2,442,075	
			Biosimilar of infliximab (Ixifi)		1,594,273	
			Biosimilar of Adalimumab (Amgevita)		3,006,282	
			Biosimilar of Rituximab (Tuxima)		2,596,299	
35	RattanaVIPapong et al., 2011	Chronic hepatitis B	Lamivudine (+Tenofovir following road map)	Palliative care	-14,000	Yes* (to Lamivudine: LMV GPO)
			Tenofovir (+ Adefovir if tolerant)		-11,000	
			Lamivudine (+Tenofovir following road map)		83,000	
			Lamivudine (+ Adefovir if tolerant)		86,000	
			Pegylated interferon first year + Tenofovir in year 3 if tolerant (+ Adefovir if tolerant)		100,000	
			Telbivudine (+ Tenofovir following road map)		116,000	
			Lamivudine (+ Adefovir following road map)		116,000	
			Pegylated interferon first year + Lamivudine in year 3 if tolerant (+ Adefovir if tolerant)		164,000	

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
			Adefovir (+ generic Lamivudine if tolerant)		164,000	
			Telbivudine (+ Adefovir if tolerant)		174,000	
			Lamivudine (+Adefovir if tolerant)		182,000	
			Entecavir (+Adefovir if tolerant)		196,000	
			Adefovir (+ Original Lamivudine if tolerant)		205,000	
			Lamivudine (+ Adefovir following road map)		212,000	
			Telbivudine (+ Adefovir following road map)		220,000	
			Pegylated interferon (first year) + Adefovir in year 3 if tolerant (+ generic Lamivudine if tolerant)		221,000	
			Pegylated interferon (first year) + Telbivudine in year 3 if tolerant (+Adefovir if tolerant)		230,000	
			Pegylated interferon (first year) + Lamivudine in year 3 if tolerant (+Adefovir if tolerant)		238,000	
			Pegylated interferon (first year) + Entecavir in year 3 if tolerant (+Adefovir if tolerant)		246,000	
			Pegylated interferon (first year) + Adefovir in year 3 if tolerant (+ original Lamivudine if tolerant)		253,000	
36	Kapol et al., 2011		Interferon + Ribavirin	Palliative care	-14,754	No

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?		
		Chronic hepatitis C (type 1 4 5 6)	Pegylated interferon alpha 2a + Ribavirin		86,600			
			Pegylated interferon alpha 2b (1.0) + Ribavirin		132,000			
			Pegylated interferon alpha 2b (1.5) + Ribavirin		188,000			
			Chronic hepatitis C (type 2 3)		Interferon + Ribavirin		-119,000	
							Pegylated interferon alpha 2a + Ribavirin	-93,000
							Pegylated interferon alpha 2b (1.0) + Ribavirin	-93,000
							Pegylated interferon alpha 2b (1.5) + Ribavirin	-75,000
37	Mohara et al., 2011	Severe lupus nephritis	Intravenous Cyclophosphamide + Azathioprine	Intravenous Cyclophosphamide + intravenous cyclophosphamide	-436,000	Yes		
			Intravenous Cyclophosphamide + Mycophenolate mofetil		774,000	No		
			Mycophenolate mofetil + Mycophenolate mofetil + Azathioprine		592,000			
			Mycophenolate mofetil + Mycophenolate mofetil + Mycophenolate mofetil		1,298,000			
38	Tosanguan et al., 2011	Tobacco cessation	Quitline	Self-cessation	-47,788	Yes*		
			Counseling in hospital		-35,088			
			Counseling with NRT gum		-32,247			
			Counseling eith NRT patch		-15,333			
			Counseling with bupropion		-32,938			

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
			Counseling with nortriptyline		-48,042	
			Counseling with varenicline		-38,959	
39	Wongpun et al., 2011	Severe asthma	Omalizumab	Standard treatment	689,045	No
40	Pantumongkol et al., 2011	Implant dentures	Implant denture	Complete denture	5,147	No
41	Tanmukayakul et al., 2011	Urinary and faecal incontinence	Disposable adult diaper	Do nothing	53,770	No
42	RattanaVIPapong et al., 2013	Epilepsy	HLA-B*15:02 screening	No screening	222,000	Yes*
		Neuropathic pain	HLA-B*15:02 screening		130,000	
43	Kittrongsiri et al., 2014	Colorectal cancer	Colorectal cancer screening among Thai general population using Fecal immunochemical test (FIT) as primary screening method	No screening	65,200	Yes
			Colorectal cancer screening among persons at increased risk with a family history of colorectal cancer in first-degree relatives using colonoscopy (COL) as primary screening method		18,300	
44	Maleewong et al., 2007	Osteoporosis	Dual energy X-ray absorptiometry (DEXA)	No screening	695,153	No
			A systematic screening using the osteoporosis self-assessment tool (OST) at first, then DEXA for selected group		688,358	
45	Kingkaew et al., 2009	Hearing loss (pre-lingual deaf children)	Cochlear implantation	Do nothing	401,000	No

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
		Hearing loss (pre-lingual deaf adults)			463,000	
		Hearing loss (post-lingual deaf adults)			368,000	
46	Leelahavarong et al., 2010	HIV	Prime-Boost (ALVAC-HIV and AIDSVAX B/E)	Existing HIV prevention program	157,000	N/A
47	Teerawattananon et al., 2010	Cataract surgery	Foldable lens	Rigid non-foldable lens	507,127	Yes*
48	Thiboonboon et al 2013	Phenylketonuria (PKU)	Tandem mass spectrometry	Guthrie test	1,043,331	No
		Isovaleric acidemia (IVA)				
		Methylmalonic acidemia (MMA)				
		Propionic acidemia (PA)				
		Maple syrup urine disease (MSUD)				
		Multiple carboxylase deficiency (MCD)				
49	Maneeon et al., 2013	Hepatocellular carcinoma	Conventional magnetic resonance imaging (cMRI)	Multiple Detector Computed Tomography (MDCT)	680,272	N/A
			Gadoxetic acid enhanced MRI (Gd-MRI)		113,450	
50	Deebukham et al., 2557	DM type 1 (aged 15)	SMBG	No SMBG	119,495	Yes*
		DM type 1 (aged 20)			118,977	
		DM type 1 (aged 30)			117,783	
		DM type 2 (aged 30)			1,013,936	
		DM type 2 (aged 40)			1,091,926	
		DM type 2 (aged 50)			1,182,139	

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
		DM type 2 (aged 60)			1,253,980	
51	Yamabhai et al., 2015	Cervix uteri cancer	Liquid-based cytology (LC)	Pap smear or conventional cytology (CC)	N/A	Yes
			Co-testing of HPV DNA and LC			
			HPV DNA (negative) and co-testing			
			Conventional cytology (negative) and HPV DNA			
52	Kumdee et al., 2016	Oral cancer	Oral cancer screening	No screening	313,391	No
53	Leelahavarong et al., 2018	Alcohol use	MMC plus community-based campaigns	Mass media campaign (MMC)	19,370	Under consideration
54	Kingkaew et al., 2019	Tobacco use	Capacity-enhanced messages	Do nothing	-489,067	Under consideration
			Motivation-enhanced messages		-489,252	
			Opportunity-enhanced messages		-489,254	
			C and M -enhanced messages		-487,361	
			C and O -enhanced messages		-489,521	
			O and M -enhanced messages		-489,048	
			C and O and M -enhanced messages		-487,612	
			Neutral messages		-488,188	
55	Pantumongkol et al., 2019	Non-small cell lung cancer	PET/CT when CT N0/1	Computed Tomography (CT)	Dominated	Under consideration
			PET/CT when CT N2/3			
			PET/CT when CT N0-3			
			PET/CT			
		Colorectal cancer	CT + PET/CT		8,198,877	
		Hodgkin lymphoma (Initial staging)	PET/CT		67,086	

No.	First author and year	Indications	Interventions	Comparators	ICER (THB/QALY gained)	Coverage decision – technology adopted?
		Hodgkin lymphoma (Interim evaluation)			45,138	
		Hodgkin lymphoma (Final evaluation)			19,026	

Note: THB: Thai Baht; QALY: quality-adjusted life years. USD1 = THB33.4231.

* Positive decision after further price negotiation, limitation of coverage to certain patient sub groups or funding pilot programmes